Table 2.

Tumour responses 4 weeks after first TACE in patients randomised to the TACE plus sorafenib and TACE alone groups results reported as N (%)

	TACE plus sorafenib (n=80)	TACE alone (n=76)	P value*
Best response			0.77
Complete response (CR)	23 (28.8)	21 (27.6)
Partial response (PR)	34 (42·.5)	26 (34.2)
Stable disease (SD)	10 (12.5)	12 (15.8)
Progressive disease (PD)	2 (2.5)	3 (3.9)
Not evaluable	11 (13.8)	14 (18.4)
ORR (CR+PR)	57 (71.3)	47 (61.8)	0.23
DCR (CR+PR+SD)	67 (83.8)	59 (77.6)	0.42

*By two-sided Fisher’s exact tests.

DCR, disease control rate; ORR, objective response rate; TACE, transarterial chemoembolisation.